GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the Company).
On 31 December 2015, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2015; calculated using an average price of £13.83 per Ordinary Share and $40.98 per ADS:
Non-Executive Director |
Ordinary Shares |
No. of ADSs |
Sir Philip Hampton |
46.839 |
|
Prof Sir Roy Anderson |
1,182.404 |
|
Dr Stephanie Burns |
|
1,036.128 |
Stacey Cartwright |
364.492 |
|
Lynn Elsenhans |
|
542.905 |
Judy Lewent |
|
320.781 |
Sir Deryck Maughan |
|
2,621.255 |
Dr Daniel Podolsky |
|
1,895.600 |
Urs Rohner |
17.420 |
|
Hans Wijers |
175.329 |
|
The Company and the Non-Executive Directors were informed of these allocations on 4 January 2016.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
4 January 2016